SpectraScience WavSTAT Optical Biopsy System Featured at Endocsopic Controversies in Gastrointestinal Disease Symposium in Copenhagen, Denmark

SAN DIEGO, Sept. 23, 2013 (GLOBE NEWSWIRE) -- SpectraScience, Inc. (OTCQB:SCIE), a San Diego-based medical device company, announced that its WavSTAT Optical Biopsy System was featured at the annual symposium on Endoscopic Controversies in Gastrointestinal Disease sponsored by the European Society of Gastrointestinal Endoscopy (ESGE). This year's conference was held at Copenhagen University Hospital in Copenhagen, Denmark on the 19th and 20th of September.

Dr. Lene Brink performed a live colonoscopy utilizing the WavSTAT4 Optical Biopsy System to definitively diagnose small and diminutive polyps and lesions discovered during the demonstration procedure. Both Denmark and Sweden have established Nurse Endoscopist programs where specially trained nurses perform many screening colonoscopies.

"Hospitals with established nurse endoscopist programs are looking for ways to provide their nurses with a diagnostic capability equal to or better than that of experienced gastroenterologists," said Michael Oliver, SpectraScience's Chief Executive Officer. "Providing the tools to permit expert diagnosis by nurses makes the entire colorectal cancer screening system more efficient. Automated assessment tools, like WavSTAT4 allow the nurses to operate more independently and efficiently. In addition, the supervising gastroenterologist is more effective as his minute-to-minute workload is reduced. This is a real advantage, both clinically and economically to the hospital, the endoscopists and the patient."

About the European Society of Gastrointestinal Endoscopy

The ESGE was officially established in 1964 to promote endoscopy. The Society has a variety of workshops, grant programs and education and research committees all focused on the first and foremost aim of the ESGE: the promotion of good endoscopy.

About SpectraScience, Inc.

SpectraScience is a San Diego based medical device company that designs, develops, manufactures and markets light-based analysis systems capable of determining whether tissue is normal, pre-cancerous or cancerous without physically removing tissue from the body. The WavSTAT Optical Biopsy System uses light to optically diagnose tissue and provide the physician with an immediate analysis. With approval for sale under the CE Mark for the European Union, the WavSTAT System is the first commercially available product that incorporates this innovative technology for clinical use.

Forward-Looking Statements

This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe," "estimate," "project," "expect" or similar expressions. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, acceptance of the Company's products and services in the marketplace, competitive factors, dependence upon third-party vendors, and other risks detailed in the Company's periodic report filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release.

CONTACT: SpectraScience, Inc. Michael Oliver, Chief Executive Officer (858) 405-9933Source:SpectraScience, Inc.